Michelle Hessen, OD, discusses how cyclosporine ophthalmic solution 0.09% is safe to use in patients with dry eye, as well as where future research should turn.
Michelle Hessen, OD, assistant professor of ophthalmology at the Wilmer Eye Institute at Johns Hopkins Medicine, spoke about the future direction of study when focusing on cyclosporine ophthalmic solution 0.09% (Cequa; Sun Pharmaceutical) and how it can help those with uncontrollable dry eye.
This transcript has been lightly edited for clarity; captions were auto-generated.
Transcript
Should cyclosporine ophthalmic solution, 0.09%, be used indefinitely?
That's a great question. In the treatment of dry eye, we not only want to improve patient symptoms, but as well as the signs of their dry eye, meaning the corneal fluorescein staining, as well as lissamine green staining. As long as these patients are continuing to improve and are comfortable, I would probably continue them on the Cequa, unless otherwise indicated as this is a very safe drug, and most patients tolerate it very well, despite some mild installation irritation,
How accessible is this treatment for patients?
At this time, I feel like Cequa accessibility has improved greatly over the last probably couple of years, such that it is covered by most commercial insurances, as well as some Medicare plans and Medicaid.
What should research into uncontrollable dry eye focus on in the future?
I think one area that that should still be studied is that [in] patients with severe corneal and conjunctival staining, if an increased dose of Cequa would give any additional benefit as compared to the twice-daily dosing.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Assay Finds Patients Who Will Benefit From Adjuvant Chemotherapy in Early-Stage NSCLC
May 31st 2025Today, cancer stage and tumor size tell which patients will receive adjuvant chemotherapy. But the rise of biomarker testing and artificial intelligence could offer new tools for assessing risk.
Read More